Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 11/20 | 0.65 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | PDE5A | O76074 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332738 | 0.89 | AMY1A (0.67) | AMY1ASLC2A1NPC1RAB9APOLB | |
| SCHEMBL3337825 | 0.84 | PDE2A (0.66) | AMY1ASLC2A1NPC1RAB9APOLB | |
| SCHEMBL23758274 | 0.83 | AMY1A (0.64) | AMY1ASLC2A1FGFR1PDE5A | |
| SCHEMBL10745653 | 0.83 | CDK4 (0.65) | AMY1ASLC2A1NPC1RAB9AKDM4E | |
| SCHEMBL20445432 | 0.83 | AMY1A (0.81) | AMY1AKDM4EALDH1A1PDE5A | |
| SCHEMBL7270233 | 0.83 | PDE5A (0.55) | AMY1ANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL3336470 | 0.82 | AMY1A (0.67) | AMY1A | |
| SCHEMBL10670451 | 0.82 | AMY1A (0.56) | AMY1APDE5A | |
| SCHEMBL31027930 | 0.82 | AMY1A (0.76) | AMY1ASLC2A1NPC1RAB9AKDM4E | |
| SCHEMBL2096956 | 0.82 | AMY1A (0.76) | AMY1ASLC2A1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2483247-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039130-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-07 | — | — | WO | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | AMY1A 2530/4885SLC2A1 4412/4885NPC1 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.